{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:41:41Z","timestamp":1769946101114,"version":"3.49.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>To date, the apocrine variant of lobular carcinoma in situ (AP-LCIS) has been cursorily described as a subtype of lobular carcinoma in situ (LCIS). We retrospectively reviewed 34 cases of AP-LCIS (including 23 associated with invasive lobular carcinoma) to fully characterize it. AP-LCIS typically presented with screen-detected calcifications in older women (mean age: 65\u2009y) and was characterized by distended terminal duct lobular units with relatively large \u201cpleomorphic\u201d cells, central necrosis, and calcifications. AP-LCIS cells exhibited abundant eosinophilic occasionally granular cytoplasm, hyperchromatic nuclei, and prominent nucleoli. Synchronous classic and\/or florid LCIS was identified in 24\/34 (70%) AP-LCIS, and in 9\/11 (82%) pure AP-LCIS. Most (68%) cases of AP-LCIS were estrogen receptor\u2013positive (50% strongly), 35% were progesterone receptor\u2013positive, 26% were human epidermal growth factor 2\u2013positive, 18% demonstrated high-proliferation rate (Ki67: &gt;15%), and 90% were androgen receptor\u2013positive. Aurora kinase A, immunoreactive in 38% of AP-LCIS cases, was not significantly associated with recurrence, development of invasion, or nodal positivity (<jats:italic toggle=\"yes\">P<\/jats:italic>&gt;0.05). Compared with conventional (nonapocrine) pleomorphic lobular carcinoma in situ (P-LCIS), aurora kinase A was expressed in a significantly greater proportion of P-LCIS (100%). AP-LCIS and P-LCIS did not otherwise differ in clinicopathologic features. Next-generation sequencing utilizing the Oncomine Comprehensive Panel v2, performed on 27 AP-LCIS cases, showed no specific molecular findings. In a mean follow-up of 57 months, 2 (of 11, 18%) pure AP-LCIS cases recurred (2 both in situ and invasive) and none metastasized or proved fatal. AP-LCIS should be regarded as another high-grade LCIS similar to P-LCIS in many respects, and pending additional studies should be managed similarly.<\/jats:p>","DOI":"10.1097\/pas.0000000000001493","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T01:32:06Z","timestamp":1587519126000},"page":"1092-1103","source":"Crossref","is-referenced-by-count":17,"title":["Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ"],"prefix":"10.1097","volume":"44","author":[{"given":"Elaine","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A.","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1200\/JCO.2005.04.038","article-title":"Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data","volume":"23","author":"Chuba","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.humpath.2013.04.004","article-title":"Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ","volume":"44","author":"Shin","year":"2013","journal-title":"Hum Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-017-4334-1","article-title":"Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow up and centralized pathology review","volume":"165","author":"De Brot","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PAS.0000000000001191","article-title":"Pleomorphic and florid lobular carcinoma in situ variants of the breast: a clinicopathologic study of 85 cases with and without invasive carcinoma from a single academic center","volume":"43","author":"Shamir","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0046-8177(92)90321-S","article-title":"Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation","volume":"23","author":"Eusebi","year":"1992","journal-title":"Hum Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/PAS.0b013e3181b18a89","article-title":"Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast","volume":"33","author":"Chen","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/PAS.0b013e31817dc3a6","article-title":"Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile","volume":"32","author":"Chivukula","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jclinpath-2018-205484","article-title":"Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast","volume":"72","author":"D\u2019Arcy","year":"2019","journal-title":"J Clin Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge database","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1242\/dmm.006395","article-title":"Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice","volume":"4","author":"Derksen","year":"2011","journal-title":"Dis Model Mech"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","article-title":"Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk","volume":"33","author":"King","year":"2015","journal-title":"J Clin Oncol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/sj.onc.1207439","article-title":"Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions","volume":"23","author":"Sarri\u00f3","year":"2004","journal-title":"Oncogene"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/jcp.2006.040626","article-title":"Non-operative breast pathology: apocrine lesions","volume":"60","author":"Wells","year":"2007","journal-title":"J Clin Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s004280050089","article-title":"Apocrine epithelium of the breast: does it result from metaplasia?","volume":"431","author":"Viacava","year":"1997","journal-title":"Virchows Arch"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1002\/1097-0142(19801201)46:11<2463::AID-CNCR2820461127>3.0.CO;2-#","article-title":"Apocrine differentiation in human mammary carcinoma","volume":"46","author":"Mossler","year":"1980","journal-title":"Cancer"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0046-8177(84)80053-2","article-title":"Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic, and ultrastructural study","volume":"15","author":"Eusebi","year":"1984","journal-title":"Hum Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/01913128009141441","article-title":"Ultrastructural analysis of apocrine carcinoma of the human breast","volume":"1","author":"Roddy","year":"1980","journal-title":"Ultrastruct Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/jcp.52.11.838","article-title":"Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors","volume":"52","author":"Selim","year":"1999","journal-title":"J Clin Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jclinpath-2018-205485","article-title":"Apocrine lesions of the breast: part 2 of a two-part review: invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast","volume":"72","author":"D\u2019Arcy","year":"2019","journal-title":"J Clin Pathol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","article-title":"Identification of molecular apocrine breast tumours by microarray analysis","volume":"24","author":"Farmer","year":"2005","journal-title":"Oncogene"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1586\/14737159.2015.1057125","article-title":"Molecular and diagnostic features of apocrine breast lesions","volume":"15","author":"Gromov","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"R26-20230922","first-page":"105","article-title":"Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: a marker of apocrine epithelium and breast carcinomas with apocrine features","volume":"110","author":"Mazoujian","year":"1983","journal-title":"Am J Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/pin.12781","article-title":"Mixed pleomorphic lobular and apocrine carcinoma of the breast: a case report suggesting pathogenesis","volume":"69","author":"Ishii","year":"2019","journal-title":"Pathol Int"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/bjc.2012.167","article-title":"Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer","volume":"106","author":"Ali","year":"2012","journal-title":"Br J Cancer"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/0284186X.2017.1404126","article-title":"Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer","volume":"57","author":"Lykkesfeldt","year":"2018","journal-title":"Acta Oncol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1038\/sj.onc.1209707","article-title":"Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation","volume":"25","author":"Wang","year":"2006","journal-title":"Oncogene"},{"key":"R33-20230922","first-page":"1414","article-title":"Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis","volume":"20","author":"Cirak","year":"2015","journal-title":"J BUON"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"iii10","DOI":"10.1093\/annonc\/mdy047.090","article-title":"Aurora kinase A is an independent predictor of invasive recurrence in breast ductal carcinoma in situ","volume":"29","author":"Miligy","year":"2018","journal-title":"Ann Oncol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-07-5268","article-title":"Expression of aurora A (but not aurora B) is predictive of survival in breast cancer","volume":"14","author":"Nadler","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/1471-2407-12-562","article-title":"Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients","volume":"12","author":"Siggelkow","year":"2012","journal-title":"BMC Cancer"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1471-2407-13-217","article-title":"A comprehensive analysis of aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer","volume":"13","author":"Yamamoto","year":"2013","journal-title":"BMC Cancer"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jjco\/hyv058","article-title":"Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1038\/ncomms10180","article-title":"Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype","volume":"7","author":"Zheng","year":"2016","journal-title":"Nat Commun"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.ejso.2019.07.011","article-title":"Pre-operative management of pleomorphic and florid lobular carcinoma in situ of the breast: report of a large multi-institutional series and review of the literature","volume":"45","author":"Foschini","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/his.12353","article-title":"Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases","volume":"64","author":"Khoury","year":"2014","journal-title":"Histopathology"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1245\/s10434-015-4552-x","article-title":"Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management","volume":"22","author":"Flanagan","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T11:26:02Z","timestamp":1722770762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001493"}},"subtitle":["Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity"],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001493","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,20]]}}}